Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Tonix Pharmaceuticals Holding (TNXP) EPS (Weighted Average and Diluted) (2023 - 2025)

Tonix Pharmaceuticals Holding (TNXP) has 3 years of EPS (Weighted Average and Diluted) data on record, last reported at -$3.72 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 1517.39% year-over-year to -$3.72; the TTM value through Sep 2025 reached $279.15, up 101.64%, while the annual FY2024 figure was -$176.6, 98.8% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$3.72 in Q3 2025 per TNXP's latest filing, up from -$3.86 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $289.57 in Q4 2024 and bottomed at -$14576.8 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 3 years is -$1536.2, with a median of -$3.86 recorded in 2025.
  • The widest YoY moves for EPS (Weighted Average and Diluted): up 101.99% in 2024, down 16589.1% in 2024.
  • A 3-year view of EPS (Weighted Average and Diluted) shows it stood at -$14576.8 in 2023, then surged by 101.99% to $289.57 in 2024, then crashed by 101.28% to -$3.72 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$3.72 in Q3 2025, -$3.86 in Q2 2025, and -$2.84 in Q1 2025.